Affinity Asset Advisors LLC Has $8.88 Million Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Affinity Asset Advisors LLC boosted its position in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 15.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 975,606 shares of the biotechnology company’s stock after acquiring an additional 130,000 shares during the period. Astria Therapeutics accounts for about 1.0% of Affinity Asset Advisors LLC’s holdings, making the stock its 26th biggest position. Affinity Asset Advisors LLC owned approximately 1.78% of Astria Therapeutics worth $8,878,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in ATXS. RA Capital Management L.P. acquired a new position in shares of Astria Therapeutics during the first quarter worth approximately $62,115,000. Perceptive Advisors LLC raised its holdings in Astria Therapeutics by 82.9% during the fourth quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock worth $30,751,000 after buying an additional 1,814,608 shares during the last quarter. Vanguard Group Inc. raised its holdings in Astria Therapeutics by 23.4% during the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock worth $35,693,000 after buying an additional 480,184 shares during the last quarter. Armistice Capital LLC bought a new position in shares of Astria Therapeutics in the fourth quarter valued at $12,119,000. Finally, Artal Group S.A. bought a new stake in shares of Astria Therapeutics during the first quarter worth about $12,445,000. Institutional investors and hedge funds own 98.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. TD Cowen initiated coverage on Astria Therapeutics in a research note on Monday, July 29th. They set a “buy” rating and a $35.00 price target for the company. Oppenheimer lifted their target price on Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a research report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Finally, Wedbush reiterated an “outperform” rating and issued a $22.00 target price on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $25.20.

Astria Therapeutics Stock Up 2.2 %

Shares of Astria Therapeutics stock opened at $12.50 on Wednesday. Astria Therapeutics, Inc. has a 1 year low of $4.26 and a 1 year high of $16.90. The stock has a fifty day moving average price of $11.35 and a 200-day moving average price of $10.88.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). As a group, equities research analysts expect that Astria Therapeutics, Inc. will post -1.66 EPS for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.